Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Shares Outstanding (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed Shares Outstanding for 17 consecutive years, with $163.1 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 1.78% to $163.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $163.1 million through Dec 2025, up 1.78% year-over-year, with the annual reading at $163.1 million for FY2025, 1.78% up from the prior year.
  • Shares Outstanding hit $163.1 million in Q4 2025 for Ironwood Pharmaceuticals, roughly flat from $162.7 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $163.4 million in Q3 2021 to a low of $153.2 million in Q2 2022.
  • Historically, Shares Outstanding has averaged $158.9 million across 5 years, with a median of $159.9 million in 2024.
  • Biggest five-year swings in Shares Outstanding: decreased 6.17% in 2022 and later increased 2.49% in 2024.
  • Year by year, Shares Outstanding stood at $162.0 million in 2021, then decreased by 4.94% to $154.0 million in 2022, then rose by 1.51% to $156.4 million in 2023, then increased by 2.46% to $160.2 million in 2024, then increased by 1.78% to $163.1 million in 2025.
  • Business Quant data shows Shares Outstanding for IRWD at $163.1 million in Q4 2025, $162.7 million in Q3 2025, and $162.4 million in Q2 2025.